D. Kempf

发表

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

D. Ho, M. Markowitz, J. Leonard, 1996, Nature Medicine.

Selection of Resistance in Protease Inhibitor-Experienced, Human Immunodeficiency Virus Type 1-Infected Subjects Failing Lopinavir- and Ritonavir-Based Therapy: Mutation Patterns and Baseline Correlates

A. Molla, D. Kempf, H. Mo, 2005, Journal of Virology.

NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein.

P. Hajduk, D. Egan, T. Holzman, 1997, Journal of medicinal chemistry.

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

J. Mellors, D. Kempf, J. Coffin, 2008, Proceedings of the National Academy of Sciences.

Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy.

A. Molla, S. Vasavanonda, D. Norbeck, 1998, Journal of medicinal chemistry.

Synthetic chemical diversity: solid phase synthesis of libraries of C2 symmetric inhibitors of HIV protease containing diamino diol and diamino alcohol cores.

D. Kempf, G. Krafft, N. Wideburg, 1995, Journal of medicinal chemistry.

Synthetic Chemical Diversity: Solid Phase Synthesis of Libraries of C2 Symmetric Inhibitors of HIV Protease Containing Diamino Diol and Diamino Alcohol Cores.

D. Kempf, Gary T. Wang, G. Krafft, 1995 .

Evaluation of substituted benzamides as P2 ligands for symmetry-based inhibitors of HIV protease

S. Vasavanonda, D. Norbeck, D. Kempf, 1995 .

Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.

D. Norbeck, D. Kempf, J. Erickson, 1990, Science.

Influence of Stereochemistry on Activity and Binding Modes for C2 Symmetry-Based Diol Inhibitors of HIV-1 Protease

Dale J. Kempf, John W. Erickson, Eric T. Baldwin, 1994 .

Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor.

D. Kempf, J. Randolph, W. Kati, 2008, Bioorganic & medicinal chemistry letters.

Stereocontrolled synthesis of C2-symmetric and pseudo-C2-symmetric diamino alcohols and diols for use in HIV protease inhibitors

D. Norbeck, D. Kempf, R. Henry, 1992 .

Evaluation of furofuran as a P2 ligand for symmetry-based HIV protease inhibitors

S. Vasavanonda, D. Norbeck, D. Kempf, 1996 .

Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis

J. Archer, A. Hoerauf, D. Kempf, 2019, Science Translational Medicine.

In vivo kinetics of Wolbachia depletion by ABBV-4083 in L. sigmodontis adult worms and microfilariae

A. Hoerauf, D. Kempf, S. Ward, 2019, PLoS neglected tropical diseases.

Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System

A. Molla, D. Kempf, M. King, 2007, Antimicrobial Agents and Chemotherapy.

In Vitro Characterization of A-315675, a Highly Potent Inhibitor of A and B Strain Influenza Virus Neuraminidases and Influenza Virus Replication

F. Hayden, L. Gubareva, A. Molla, 2002, Antimicrobial Agents and Chemotherapy.

Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned.

Dustin J Maly, D. Kempf, R. Hackman, 2020, International journal for parasitology.

Novel hepatitis C virus replicon inhibitors: synthesis and structure-activity relationships of fused pyrimidine derivatives.

A. C. Krueger, A. Molla, D. Kempf, 2012, Bioorganic & Medicinal Chemistry Letters.

Hepatitis C NS5B polymerase inhibitors: 4,4-Dialkyl-1-hydroxy-3-oxo-3,4-dihydronaphthalene-3-yl benzothiadiazine derivatives.

V. Stoll, A. Molla, D. Kempf, 2008, Bioorganic & medicinal chemistry letters.

Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of unsymmetrical 1-hydroxy-4,4-dialkyl-3-oxo-3,4-dihydronaphthalene benzothiadiazine derivatives.

A. C. Krueger, A. Molla, D. Kempf, 2007, Bioorganic & medicinal chemistry letters.

Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-alkyl-4-hydroxyquinolon-3-yl-benzothiadiazine sulfamides.

A. C. Krueger, A. Molla, D. Kempf, 2006, Bioorganic & medicinal chemistry letters.

Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-1-heteroalkyl-4-hydroxyquinolon-3-yl-benzothiadiazines.

A. Molla, D. Kempf, H. Mo, 2005, Bioorganic & medicinal chemistry letters.

The Tuberculosis Drug Accelerator at year 10: what have we learned?

H. M. Petrassi, Christopher B. Cooper, Robert H Bates, 2021, Nature Medicine.

In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450

A. Molla, D. Kempf, Liangjun Lu, 2014, Antimicrobial Agents and Chemotherapy.

Virtual Inhibitory Quotient Predicts Response to Ritonavir Boosting of Indinavir-Based Therapy in Human Immunodeficiency Virus-Infected Patients with Ongoing Viremia

D. Havlir, A. Zolopa, J. Gallant, 2002, Antimicrobial Agents and Chemotherapy.

Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.

Dustin J Maly, W. Hol, M. Parsons, 2016, Journal of medicinal chemistry.

SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of Toxoplasma gondii CDPK1

Dustin J Maly, W. Hol, M. Parsons, 2015, ACS medicinal chemistry letters.

Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis.

Dustin J Maly, D. Kempf, Joachim Müller, 2017, International journal for parasitology.

A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation.

Dustin J Maly, X. Su, K. Comess, 2014, The Journal of infectious diseases.

In Vitro Selection and Characterization of Influenza A (A/N9) Virus Variants Resistant to a Novel Neuraminidase Inhibitor, A-315675

V. Stoll, A. Molla, D. Kempf, 2002, Journal of Virology.

Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors.

A. Molla, D. Kempf, H. Mo, 2006, Bioorganic & Medicinal Chemistry.

Liver transcriptomic changes associated with ritonavir-induced hyperlipidemia in sensitive and resistant strains of rats.

J. Waring, H. Jacob, D. Kempf, 2010, Veterinary journal.

Speci fi c Inhibitor of Pf CDPK 4 Blocks Malaria Transmission : Chemical-genetic Validation

X. Su, K. Comess, W. V. Voorhis, 2013 .

HIV protease inhibitor A-792611 is a novel functional inhibitor of human PXR

J. Waring, R. Kim, D. Kempf, 2007 .

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir

D. Kempf, Liangjun Lu, T. Pilot‐Matias, 2017, Antimicrobial Agents and Chemotherapy.

The Discovery and Development of HCV NS3 Protease Inhibitor Paritaprevir

D. Kempf, T. Middleton, Hui-ju Chen, 2019, Topics in Medicinal Chemistry.

Des-A-ring benzothiadiazines: inhibitors of HCV genotype 1 NS5B RNA-dependent RNA polymerase.

A. Molla, D. Kempf, W. Kati, 2008, Bioorganic & medicinal chemistry letters.

Pharmacokinetic Enhancement of the Hepatitis C Virus Protease Inhibitors VX-950 and SCH 503034 by Co-Dosing with Ritonavir

D. Kempf, J. Randolph, K. Marsh, 2007, Antiviral chemistry & chemotherapy.

Dipeptide analogs. Versatile synthesis of the hydroxyethylene isostere

D. Kempf, 1986 .

.beta.'-Lithiation of .alpha.,.beta.-unsaturated secondary amides

D. Kempf, P. Beak, 1980 .

Inhibitors of hepatitis C virus polymerase: synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazines.

A. C. Krueger, A. Molla, D. Kempf, 2009, Journal of medicinal chemistry.

Design, synthesis, and structural analysis of influenza neuraminidase inhibitors containing pyrrolidine cores.

W G Laver, S. Muchmore, V. Giranda, 2001, Journal of medicinal chemistry.

Enantioselective synthesis of antiinfluenza compound A-315675.

D. Kempf, Hui-ju Chen, L. L. Klein, 2002, The Journal of organic chemistry.

Novel lopinavir analogues incorporating non-Aromatic P-1 side chains--synthesis and structure--activity relationships.

S. Vasavanonda, D. Norbeck, D. Kempf, 2002, Bioorganic & medicinal chemistry letters.

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.

S. Vasavanonda, D. Norbeck, D. Kempf, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol.

S. Vasavanonda, D. Kempf, H. Sham, 1993, Journal of medicinal chemistry.

Hepatitis C NS5B polymerase inhibitors: functional equivalents for the benzothiadiazine moiety.

V. Stoll, A. Molla, D. Kempf, 2011, Bioorganic & medicinal chemistry letters.

Remote lithiation of N-methallyl amides

D. Kempf, 1989 .

Synthesis and biological characterization of B-ring amino analogues of potent benzothiadiazine hepatitis C virus polymerase inhibitors.

A. Molla, D. Kempf, J. Randolph, 2009, Journal of medicinal chemistry.

Stereocontrolled synthesis of Ψ[CH=CH] dipeptide isosteres

D. Kempf, S. Spanton, Xiulian Wang, 2009 .

Oximinoarylsulfonamides as potent HIV protease inhibitors.

V. Stoll, D. Kempf, J. Randolph, 2005, Bioorganic & medicinal chemistry letters.

The .beta.' lithiation of .alpha.,.beta.-unsaturated amides

K. D. Wilson, D. Kempf, P. Beak, 1985 .

Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir).

A. Molla, S. Vasavanonda, D. Norbeck, 2001, Bioorganic & medicinal chemistry letters.

Renin inhibitors based on novel dipeptide analogues. Incorporation of the dehydrohydroxyethylene isostere at the scissile bond.

D. Kempf, J. Plattner, J. Cohen, 1987, Journal of medicinal chemistry.

Dipeptide Analogues: Versatile Synthesis of the Hydroxyethylene Isostere.

D. Kempf, 1987 .

β′-LITHIATION OF α,β-UNSATURATED SECONDARY AMIDES

D. Kempf, P. Beak, 1980 .

.beta.' Metalation of .alpha.,.beta.-unsaturated tertiary amides

K. D. Wilson, D. Kempf, P. Beak, 1982 .

Dipole-stabilized carbanions: evidence for a complex in the .alpha.'-lithiation of N,N-dimethyl-2,4,6-triisopropylbenzamide

Stanley G. Smith, D. Kempf, S. Mills, 1983 .

Stereochemical studies of lasalocid epimers. Ion-driven epimerizations.

W. C. Still, D. Kempf, P. Hauck, 1987 .

Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series.

Jonathan Greer, V. Stoll, J. Greer, 2003, Biochemistry.

ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease

Dale J. Kempf, John M. Leonard, Jacob J. Plattner, 1998, Antimicrobial Agents and Chemotherapy.

In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to ABT-378, a Novel Protease Inhibitor

Dale J. Kempf, William E. Kohlbrenner, John M. Leonard, 1998, Journal of Virology.

Design, synthesis, and neuraminidase inhibitory activity of GS-4071 analogues that utilize a novel hydrophobic paradigm.

V. Stoll, D. Kempf, W. G. Laver, 2002, Bioorganic & medicinal chemistry letters.

Discovery of imidazolidine-2,4-dione-linked HIV protease inhibitors with activity against lopinavir-resistant mutant HIV.

H. Mo, D. Kempf, K. Marsh, 2006, Bioorganic & Medicinal Chemistry.

Ritonavir and saquinavir combination therapy for the treatment of HIV infection.

R Rode, M Salgo, D. Ho, 1999, AIDS.

Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease

S. Vasavanonda, D. Norbeck, D. Kempf, 1991, Antimicrobial Agents and Chemotherapy.

Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing

JD Lundgren, N Clumeck, A. D. Luca, 2004, Antiviral therapy.

A C2 symmetry-based HIV protease inhibitor, A77003, irreversibly inhibits infectivity of HIV-1 in vitro.

D. Norbeck, D. Kempf, J. Erickson, 1994, AIDS research and human retroviruses.

Lack of stereospecificity in the binding of the P2 amino acid of ritonavir to HIV protease

A. D. Rodrigues, S. Muchmore, A. Molla, 1997 .

Facile synthesis of potent HIV-1 protease inhibitors containing a novel pseudo-symmetric dipeptide isostere

D. Norbeck, D. Kempf, H. Sham, 1993 .

Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients

Richard A. Rode, Dale J. Kempf, D. Kempf, 2001, Journal of Virology.

The duration of viral suppression during protease inhibitor therapy for HIV‐1 infection is predicted by plasma HIV‐1 RNA at the nadir

J. Leonard, A. Molla, C. Boucher, 1998, AIDS.

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir

A. D. Rodrigues, J. Leonard, A. Hsu, 1997, Antimicrobial agents and chemotherapy.

Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children

O. Ramilo, A. Hsu, D. Kempf, 2003, The Pediatric Infectious Disease Journal.

Complementation in Cells Cotransfected with a Mixture of Wild-Type and Mutant Human Immunodeficiency Virus (HIV) Influences the Replication Capacities and Phenotypes of Mutant Variants in a Single-Cycle HIV Resistance Assay

A. Molla, D. Kempf, H. Mo, 2004, Journal of Clinical Microbiology.

Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model

Dale J. Kempf, William E. Kohlbrenner, Rolf Wagner, 2007, Antimicrobial Agents and Chemotherapy.

4 Pharmacokinetic boosting of VX-950, an inhibitor of HCV protease, by co-dosing with ritonavir

D. Kempf, J. Randolph, K. Marsh, 2006 .

Identiﬁcation and Structural Characterization of I84C and I84A Mutations That Are Associated with High-Level Resistance to Human Immunodeﬁciency Virus Protease Inhibitors and Impair Viral Replication (cid:1)

A. Molla, D. Kempf, N. Parkin, 2007 .

Identification and Structural Characterization of I84C and I84A Mutations That Are Associated with High-Level Resistance to Human Immunodeficiency Virus Protease Inhibitors and Impair Viral Replication

A. Molla, D. Kempf, N. Parkin, 2006, Antimicrobial Agents and Chemotherapy.

Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus.

J. Leonard, A. Molla, S. Vasavanonda, 1998, Virology.

Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease.

L. Everitt, A. Kaplan, D. Norbeck, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Discovery of pyrido[2,3-d]pyrimidine-based inhibitors of HCV NS5A.

A. Molla, D. Kempf, T. Pilot‐Matias, 2013, Bioorganic & medicinal chemistry letters.

Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.

A. Molla, D. Kempf, H. Mo, 2003, Antiviral research.

Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients

A. Hsu, G. Granneman, D. Kempf, 2003, Antimicrobial Agents and Chemotherapy.

Design of symmetry-based, peptidomimetic inhibitors of human immunodeficiency virus protease.

D. Kempf, 1994, Methods in enzymology.

Structure-based, C2 symmetric inhibitors of HIV protease.

S. Vasavanonda, D. Norbeck, D. Kempf, 1990, Journal of medicinal chemistry.

Design of orally bioavailable, symmetry-based inhibitors of HIV protease.

S. Vasavanonda, D. Kempf, H. Sham, 1994, Bioorganic & medicinal chemistry.

Potent HIV-1 protease inhibitors with antiviral activities in vitro.

S. Vasavanonda, D. Norbeck, D. Kempf, 1991, Biochemical and biophysical research communications.

Progress in the discovery of orally bioavailable inhibitors of HIV protease

D. Kempf, 1995 .

Structure-based design of symmetric inhibitors of HIV-1 protease.

D. Kempf, J. Erickson, 1994, Archives of virology. Supplementum.

Stereochemical studies of lasalocid aldol epimers. Assignments and interconversions

W. C. Still, D. Kempf, P. Hauck, 1986 .

In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations

J. Weinstein, D. Norbeck, D. Kempf, 1992, Antimicrobial Agents and Chemotherapy.

Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity

A. Hoerauf, D. Kempf, S. Ward, 2019, PLoS neglected tropical diseases.

Crystal structure of full-length Zika virus NS5 protein reveals a conformation similar to Japanese encephalitis virus NS5

K. Longenecker, Chaohong Sun, D. Kempf, 2017, Acta crystallographica. Section F, Structural biology communications.

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

D Norbeck, D. Ho, D. Norbeck, 1994, Journal of virology.

Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir.

D. Kempf, M. King, S. Brun, 2005, The Journal of infectious diseases.

In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 2 with Decreased Susceptibility to Lopinavir

F. Gao, A. Molla, D. Kempf, 2007, Antimicrobial Agents and Chemotherapy.

In Vitro Selection and Characterization of Human Immunodeﬁciency Virus Type 2 with Decreased Susceptibility to Lopinavir (cid:1)

A. Molla, D. Kempf, H. Mo, 2007 .

Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth

A. Korkegian, L. Stojanovski, K. Read, 2021, ACS omega.

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.

A. Hsu, D. Kempf, M. King, 2004, The Journal of infectious diseases.

A Human Immunodeficiency Virus Protease Inhibitor Is a Novel Functional Inhibitor of Human Pregnane X Receptor

Dale J. Kempf, Jeffrey F. Waring, J. Waring, 2008, Drug Metabolism and Disposition.

In Vitro Antiviral Interaction of Lopinavir with Other Protease Inhibitors

A. Molla, S. Vasavanonda, A. Hsu, 2002, Antimicrobial Agents and Chemotherapy.

ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia

Joseph A Kovacs, Sarah Palmer, R. Dewar, 2007, PLoS pathogens.

Estimation of Serum-Free 50-Percent Inhibitory Concentrations for Human Immunodeficiency Virus Protease Inhibitors Lopinavir and Ritonavir

S. Vasavanonda, A. Hsu, D. Kempf, 2004, Antimicrobial Agents and Chemotherapy.

Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced Patients

V. Calvez, D. Kempf, M. King, 2005, Antimicrobial Agents and Chemotherapy.

Predictive Genotypic Algorithm for Virologic Response to Lopinavir-Ritonavir in Protease Inhibitor-Experienced Patients

V. Calvez, D. Kempf, M. King, 2007, Antimicrobial Agents and Chemotherapy.

Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis.

Thomas R. Ioerger, Travis Hartman, Tom L. Blundell, 2017, ACS infectious diseases.

Clinically Validated Genotype Analysis: Guiding Principles and Statistical Concerns

Victor DeGruttola, Vincent Calvez, Maurizio Zazzi, 2004, Antiviral therapy.

Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease

J. Leonard, J. Bilello, D. Norbeck, 1996, Antimicrobial agents and chemotherapy.

Assembling Pharma Resources to Tackle Diseases of Underserved Populations.

D. Kempf, K. Marsh, 2020, ACS medicinal chemistry letters.

Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains.

V. Stoll, S. Vasavanonda, D. Norbeck, 2005, Bioorganic & medicinal chemistry letters.

Synthesis and antiviral activity of P1' arylsulfonamide azacyclic urea HIV protease inhibitors.

V. Stoll, S. Vasavanonda, D. Kempf, 2004, Bioorganic & medicinal chemistry letters.

Human immunodeficiency virus type 1 virions composed of unprocessed Gag and Gag-Pol precursors are capable of reverse transcribing viral genomic RNA

A. Kaplan, D. Norbeck, D. Kempf, 1994, Antimicrobial Agents and Chemotherapy.

Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles

A. Kaplan, D. Norbeck, D. Kempf, 1993, Journal of virology.

to a C2-symmetric protease inhibitor. virus type 1 variants with increased resistance Characterization of human immunodeficiency

D. Norbeck, D. Kempf, J. Erickson, 2016 .

Recent developments in HIV protease inhibitor therapy.

A. Molla, G. Granneman, D. Kempf, 1998, Antiviral research.

Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor

D. Ho, T. Bhat, M. Markowitz, 1995, Journal of virology.

Prevalence, Mutation Patterns, and Effects on Protease Inhibitor Susceptibility of the L76V Mutation in HIV-1 Protease

D. Kempf, N. Parkin, T. Pilot‐Matias, 2010, Antimicrobial Agents and Chemotherapy.

Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.

A. Molla, D. Kempf, R. Kuroki, 2009, Journal of medicinal chemistry.

Characterization of a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, A-790742

A. Molla, D. Kempf, L. L. Klein, 2008, Antimicrobial Agents and Chemotherapy.

Ritonavir and Lopinavir/Ritonavir

D. Kempf, 2007 .

Metabolism and Disposition of the HIV-1 Protease Inhibitor Lopinavir (ABT-378) Given in Combination with Ritonavir in Rats, Dogs, and Humans

D. Kempf, H. Sham, K. Marsh, 2004, Pharmaceutical Research.

Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P2 ligands.

S. Vasavanonda, D. Norbeck, D. Kempf, 2003, Bioorganic & medicinal chemistry letters.

Synthesis and structure-activity relationships of a novel series of HIV-1 protease inhibitors encompassing ABT-378 (Lopinavir).

S. Vasavanonda, D. Norbeck, D. Kempf, 2002, Bioorganic & medicinal chemistry letters.

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.

P. Sax, A. Hsu, D. Kempf, 2002, The Journal of infectious diseases.

Analysis of the Virological Response with Respect to Baseline Viral Phenotype and Genotype in Protease Inhibitor-Experienced HIV-1-Infected Patients Receiving Lopinavir/Ritonavir Therapy

D. Kempf, M. King, S. Brun, 2001, Antiviral therapy.

Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans.

D. Kempf, J. Denissen, A. Buko, 1997, Drug metabolism and disposition: the biological fate of chemicals.

Enantioselective Synthesis of Antiinfluenza Compound A-315675 (I).

D. Kempf, Hui-ju Chen, L. L. Klein, 2002 .

Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-1-benzyl and N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine analogs containing substituents on the aromatic ring.

A. Molla, D. Kempf, D. Beno, 2006, Bioorganic & medicinal chemistry letters.

Synthesis and SAR of novel 1,1-dialkyl-2(1H)-naphthalenones as potent HCV polymerase inhibitors.

A. Molla, D. Kempf, H. Mo, 2008, Bioorganic & medicinal chemistry letters.

Synthesis of potent pyrrolidine influenza neuraminidase inhibitors.

A. C. Krueger, A. Molla, D. Kempf, 2008, Bioorganic & medicinal chemistry letters.

2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.

V. Stoll, A. Molla, D. Kempf, 2009, Journal of medicinal chemistry.

Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.

D. Kempf, J. Randolph, K. Marsh, 2009, Bioorganic & medicinal chemistry letters.

In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification.

D. Kempf, H. Sham, D. Betebenner, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir.

A. Molla, D. Kempf, K. Marsh, 2009, Journal of medicinal chemistry.

Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket.

Kent D. Stewart, Vincent S. Stoll, Jeffrey R. Huth, 2010, Bioorganic & medicinal chemistry letters.

Novel chemical entities inhibiting Mycobacterium tuberculosis growth identified by phenotypic high-throughput screening

A. Korkegian, D. Kempf, M. Files, 2022, Scientific Reports.

Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia

J. Waring, D. Kempf, J. Randolph, 2010, Archives of Toxicology.

Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG.

Tara L. Kieffer, R. Schooley, C. Petropoulos, 2011, Gastroenterology.

Inhibitor stabilization of human immunodeficiency virus type-2 proteinase dimer formation.

T. Holzman, D. Kempf, J. Erickson, 1991, The Journal of biological chemistry.

An 'inside-the-box' approach to drug resistance.

D. Kempf, K. Stewart, 2004, Chemistry & biology.

Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors.

Vincent S Stoll, A. C. Krueger, V. Stoll, 2005, Journal of medicinal chemistry.

Comparison of Toxicities among Different Bumped Kinase Inhibitor Analogs for Treatment of Cryptosporidiosis

S. Tzipori, D. Kempf, R. Hackman, 2023, Antimicrobial agents and chemotherapy.

A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.

A. Molla, S. Vasavanonda, N. Lyons, 1996, Journal of medicinal chemistry.

Potent, low molecular weight renin inhibitors containing a C-terminal heterocycle: hydrogen bonding at the active site.

R. Maki, D. Kempf, S. Rosenberg, 1990, Journal of medicinal chemistry.

Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 Tetrahydrofuranylglycine.

D. Kempf, R. Kuroki, Y. Kiso, 2018, Journal of medicinal chemistry.

Genotypic Correlates of Reduced In Vitro Susceptibility to ABT-378 in HIV Isolates From Patients Failing Protease Inhibitor Therapy

K. Hertogs, B. Larder, D. Kempf, 1999 .

Synthesis of (2S,5S,4R)-2,5-diamino-3,3-difluoro-1,6-diphenylhydroxyhexane: the core unit of a potent HIV proteinase inhibitor

D. Norbeck, D. Kempf, J. Erickson, 1991 .

A Phase-I pharmacokinetic, safety and food-effect study on flubentylosin, a novel analog of Tylosin-A having potent anti-Wolbachia and antifilarial activity

D. Kempf, D. Cohen, K. Marsh, 2023, PLoS neglected tropical diseases.

X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease.

V. Stoll, R. Simmer, D. Norbeck, 2002, Bioorganic & medicinal chemistry.

Virologic Response to Lopinavir-Ritonavir-Based Antiretroviral Regimens in a Multicenter International Clinical Cohort: Comparison of Genotypic Interpretation Scores

R. Shafer, A. Zolopa, D. Kempf, 2008, Antimicrobial Agents and Chemotherapy.

Design, synthesis, and structural analysis of inhibitors of influenza neuraminidase containing a 2,3-disubstituted tetrahydrofuran-5-carboxylic acid core.

V. Stoll, D. Kempf, T. Sowin, 2005, Bioorganic & medicinal chemistry letters.

Synthesis of rigid, heterocyclic dipeptide analogs

D. Kempf, S. L. Condon, 1990 .

Synthesis of Rigid, Heterocyclic Dipeptide Analogues.

D. Kempf, S. L. Condon, 1990 .

Chapter 15. HIV Protease Inhibitors

D. Norbeck, D. Kempf, 1991 .

Renin inhibitors based on novel dipeptide analogs: Increased efficacy through systematic inclusion of polar functionality

D. Kempf, J. Plattner, H. Kleinert, 1988 .

Design of rigid heterocyclic phenylalanine replacements for incorporation into renin inhibitors

D. Kempf, J. Plattner, H. Kleinert, 1990 .

A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation.

Dustin J Maly, X. Su, K. Comess, 2014, The Journal of infectious diseases.

Prevalence, Mutation Patterns, and Effects on Protease Inhibitor Susceptibility of the L76V Mutation in HIV-1 Protease

D. Kempf, N. Parkin, E. Stawiski, 2010, Antimicrobial Agents and Chemotherapy.

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.

A. Hsu, D. Kempf, M. King, 2004, The Journal of infectious diseases.

Novel azacyclic ureas that are potent inhibitors of HIV-1 protease.

A. Molla, S. Vasavanonda, D. Norbeck, 1996, Biochemical and Biophysical Research Communications - BBRC.

Pseudo‐symmetrical difluoroketones

S. Vasavanonda, D. Norbeck, D. Kempf, 1993, FEBS letters.

Design and characterization of an engineered gp41 protein from human immunodeficiency virus-1 as a tool for drug discovery

Kevin Harris, Kent D. Stewart, Kevin Steffy, 2007, J. Comput. Aided Mol. Des..

Practical Preclinical Model for Assessing the Potential for Unconjugated Hyperbilirubinemia Produced by Human Immunodeficiency Virus Protease Inhibitors

J. Waring, D. Kempf, J. Randolph, 2006, Antimicrobial Agents and Chemotherapy.